Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension

Journal of Cardiac Failure

Volumn 16, Issue 2, 2010, Pages 121-127

  Blalock, Shannon E ^a   Matulevicius, Susan ^b   Mitchell, Laura C ^b   Reimold, Sharon ^b   Warner, John ^b   Peshock, Ronald ^b   Torres, Fernando ^b   Chin, Kelly M ^b  

^a Childrens Medical Center of Dallas   (United States)

^b SOUTHWESTERN UNIVERSITY   (United States)

Author keywords

6 minute walk test; cardiac MRI; Pulmonary hypertension; right ventricle

Indexed keywords

AMBRISENTAN; FENFLURAMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXERCISE TEST; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART OUTPUT; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; IDIOPATHIC DISEASE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIX MINUTE WALK DISTANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHENYLPROPIONATES; PYRIDAZINES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75149115729     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.09.008     Document Type: Article

References (19)

1. Channick R.N., Sitbon O., Barst R.J., Manes A., and Rubin L.J. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 43 12 Suppl S (2004) 62S-67S
2. Galie N., Olschewski H., Oudiz R.J., Torres F., Frost A., Ghofrani H.A., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117 (2008) 3010-3019
3. Galie N., Badesch D., Oudiz R., Simonneau G., McGoon M.D., Keogh A.M., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 529-535
4. Lorenz C.H., Walker E.S., Morgan V.L., Klein S.S., and Graham Jr. T.P. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1 (1999) 7-21
5. van Wolferen S.A., Marcus J.T., Boonstra A., Marques K.M., Bronzwaer J.G., Spreeuwenberg M.D., et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 28 (2007) 1250-1257
6. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
7. Sitbon O., Badesch D.B., Channick R.N., Frost A., Robbins I.M., Simonneau G., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 124 (2003) 247-254
8. Provencher S., Sitbon O., Humbert M., Cabrol S., Jais X., and Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27 (2006) 589-595
9. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galie N., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
10. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
11. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
12. Roeleveld R.J., Vonk-Noordegraaf A., Marcus J.T., Bronzwaer J.G., Marques K.M., Postmus P.E., et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest 125 (2004) 572-579
13. Hinderliter A.L., Willis P.W.T., Barst R.J., Rich S., Rubin L.J., Badesch D.B., et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 95 (1997) 1479-1486
14. Galie N., Hinderliter A.L., Torbicki A., Fourme T., Simonneau G., Pulido T., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 1380-1386
15. Chin K.M., Kingman M., de Lemos J.A., Warner J.J., Reimold S., Peshock R., et al. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. Am J Cardiol 101 (2008) 1669-1672
16. Reesink H.J., Marcus J.T., Tulevski I.I., Jamieson S., Kloek J.J., Vonk Noordegraaf A., et al. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg 133 (2007) 58-64
17. Kasimir M.T., Seebacher G., Jaksch P., Winkler G., Schmid K., Marta G.M., et al. Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation. Eur J Cardiothorac Surg 26 (2004) 776-781
18. Grothues F., Moon J.C., Bellenger N.G., Smith G.S., Klein H.U., and Pennell D.J. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 147 (2004) 218-223
19. Voelkel N.F., Quaife R.A., Leinwand L.A., Barst R.J., McGoon M.D., Meldrum D.R., et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114 (2006) 1883-1891